The reprogramming of TME such as hypoxia, inflammatory cytokines, abnormal pH, or altered crosstalk between tumor cells and microenvironment as disease progresses also accelerates a secondary STAT3 activation following primary therapy [172, 173]. This evidence concerns the gene STAT3 and neoplasm.